ATE312102T1 - Xanthinderivate und analoge als zellsignalisierung inhibitoren - Google Patents

Xanthinderivate und analoge als zellsignalisierung inhibitoren

Info

Publication number
ATE312102T1
ATE312102T1 AT00921774T AT00921774T ATE312102T1 AT E312102 T1 ATE312102 T1 AT E312102T1 AT 00921774 T AT00921774 T AT 00921774T AT 00921774 T AT00921774 T AT 00921774T AT E312102 T1 ATE312102 T1 AT E312102T1
Authority
AT
Austria
Prior art keywords
independently selected
analogues
membered ring
ring structure
group
Prior art date
Application number
AT00921774T
Other languages
English (en)
Inventor
J Peter Klein
Stephen J Klaus
Anil M Kumar
Baoqing Gong
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/288,556 external-priority patent/US6774130B2/en
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Application granted granted Critical
Publication of ATE312102T1 publication Critical patent/ATE312102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00921774T 1999-04-09 2000-04-07 Xanthinderivate und analoge als zellsignalisierung inhibitoren ATE312102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/288,556 US6774130B2 (en) 1998-01-16 1999-04-09 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
PCT/US2000/009139 WO2000061583A1 (en) 1995-06-07 2000-04-07 Xanthine derivatives and analogs as cell signaling inhibitors

Publications (1)

Publication Number Publication Date
ATE312102T1 true ATE312102T1 (de) 2005-12-15

Family

ID=23107627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921774T ATE312102T1 (de) 1999-04-09 2000-04-07 Xanthinderivate und analoge als zellsignalisierung inhibitoren

Country Status (9)

Country Link
EP (1) EP1171442B1 (de)
JP (1) JP2002541258A (de)
AT (1) ATE312102T1 (de)
AU (1) AU4205000A (de)
CA (1) CA2369981A1 (de)
DE (1) DE60024604T2 (de)
ES (1) ES2254163T3 (de)
MX (1) MXPA01010143A (de)
WO (1) WO2000061583A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
HRP20130406T1 (hr) 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a
JP2005320309A (ja) * 2004-05-02 2005-11-17 Hokkaido Technology Licence Office Co Ltd 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬
EP1841448A2 (de) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
JP5112316B2 (ja) 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
EP2325169B1 (de) 2005-08-29 2015-10-07 University Of Virginia Patent Foundation Lisofylline-analogue und ihre pharamazeutische verwendungen
EP2056833A2 (de) * 2006-08-23 2009-05-13 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Harn- und thioharnsäurederivate für erkrankungen in verbindung mit oxidativem stress
EP1939197A1 (de) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-Ethinylxanthinderivate als selektive Antagonisten des A2A-Rezeptors
RU2459826C1 (ru) * 2011-05-31 2012-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Циклогексиламмониевая соль [3-метил-1-н-пропил-7-(1-оксотиетанил-3)ксантинил-8-тио]уксусной кислоты, проявляющая антитромботическую активность
RU2459825C1 (ru) * 2011-05-31 2012-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Соли [3-метил-1-н-пропил-7-(1,1-диоксотиетанил-3)ксантинил-8-тио]уксусной кислоты, проявляющие проагрегантную активность
ES2665580T3 (es) * 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
UA117470C2 (uk) * 2013-03-15 2018-08-10 Гайдра Байосаєнсиз, Інк. Заміщені ксантини та способи їх застосування
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
AU2016359626A1 (en) 2015-11-25 2018-05-17 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
EA201890913A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс Пиразоловые соединения в качестве ингибиторов акк и их применение
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
BR112018067408A2 (pt) 2016-03-02 2018-12-26 Gilead Apollo Llc formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3515919A1 (de) 2016-09-23 2019-07-31 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
RU2740926C1 (ru) * 2020-09-02 2021-01-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные тиетансодержащих 1-бутил-3-метилксантинов, проявляющие антиоксидантную активность
CN119569744B (zh) * 2024-11-19 2026-01-02 武汉大学人民医院（湖北省人民医院） 吡喃吡啶酮生物碱类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) * 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) * 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
AU1967495A (en) * 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds

Also Published As

Publication number Publication date
EP1171442B1 (de) 2005-12-07
DE60024604T2 (de) 2006-08-24
ES2254163T3 (es) 2006-06-16
AU4205000A (en) 2000-11-14
MXPA01010143A (es) 2003-07-14
JP2002541258A (ja) 2002-12-03
CA2369981A1 (en) 2000-10-19
DE60024604D1 (de) 2006-01-12
EP1171442A1 (de) 2002-01-16
WO2000061583A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
DE60024604D1 (de) Xanthinderivate und analoge als zellsignalisierung inhibitoren
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
NO20055316L (no) Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike
ES2075036T3 (es) 3-piperidinil-1,2-benzoisoxazoles.
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO20072116L (no) Farmasoytiske forbindelser
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
BG103984A (en) Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
DK1158973T3 (da) Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
MXPA03005822A (es) Compuestos heterociclicos que tienen actividad antibacteriana, proceso para su preparacion y composiciones farmaceuticas que los contienen.
EP1396493A4 (de) Heterocyclische verbindungen
AP2002002530A0 (en) 2,4 diaminopyrimidine compounds useful as immunosuppressants.
ES8801245A1 (es) Un procedimiento para preparar derivados de piperidina
DE3065304D1 (en) Morpholine derivatives, pharmaceutical compositions containing them and processes for their preparation
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
RU97103983A (ru) Лекарственные композиции и производные триазина
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
DK0587645T3 (da) Benzo- og pyridopyranderivater med anxiolytisk og antikonvulsiv aktivitet
MY143578A (en) Piperazinediones as oxytocin receptor antagonists
AR024146A1 (es) Derivados de 4-fenil-pirimidina
AR027578A1 (es) Derivados de indano

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties